Publications by authors named "Marc Hyer"

Claim this Profile
T
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.
John Maris, Isabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, David Groff, Marc Hyer

Res Sq· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.
Frédéric Vallée, Matias Casás-Selves, Monica Bubenik, Martin Duplessis, Boubacar Sow, Marc Hyer

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Haineng Xu, Erin George, David Gallo, Sergey Medvedev, Xiaolei Wang, Marc L Hyer

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reciprocal links between methionine metabolism, DNA repair and therapy resistance in glioblastoma.
Navyateja Korimerla, Baharan Meghdadi, Isra Haq, Kari Wilder-Romans, Jie Xu, Marc L Hyer

bioRxiv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Anran Chen, Beom-Jun Kim, Aparna Mitra, Craig T Vollert, Jonathan T Lei, Marc L Hyer

Mol Cancer Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Haineng Xu, Erin George, David Gallo, Sergey Medvedev, Xiaolei Wang, Marc L Hyer

Res Sq· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.
Emily Gruber, Joan So, Alexander C Lewis, Rheana Franich, Rachel Cole, Marc L Hyer

Cell Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
Pavlina Chuntova, Akane Yamamichi, Tiffany Chen, Rohini Narayanaswamy, Sebastien Ronseaux, Marc L Hyer

J Immunother Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
Mingzong Li, Zenon Konteatis, Nelamangala Nagaraja, Yue Chen, Shubao Zhou, Marc L Hyer

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous Deletion.
Zenon Konteatis, Jeremy Travins, Stefan Gross, Katya Marjon, Amelia Barnett, Marc L Hyer

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Peter Kalev, Marc L Hyer, Stefan Gross, Zenon Konteatis, Chi-Chao Chen

Cancer Cell· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Junling Zhuang, Fazal Shirazi, Ram Kumar Singh, Isere Kuiatse, Hua Wang, Marc Hyer

Blood· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Samir H Barghout, Parasvi S Patel, Xiaoming Wang, G Wei Xu, Simon Kavanagh, Marc L Hyer

Leukemia· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Pu Shi, Mingxiang Liao, Bei-Ching Chuang, Robert Griffin, Judy Shi, Marc Hyer

Xenobiotica· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.
Marc L Hyer, Michael A Milhollen, Jeff Ciavarri, Paul Fleming, Tary Traore

Nat Med· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines.
Denise L Driscoll, Arijit Chakravarty, Doug Bowman, Vaishali Shinde, Kerri Lasky, Marc L Hyer

PLoS One· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Jessica J Huck, Mengkun Zhang, Jerome Mettetal, Arijit Chakravarty, Karthik Venkatakrishnan, Marc L Hyer

Mol Cancer Ther· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
Judy Quiju Shi, Kerri Lasky, Vaishali Shinde, Bradley Stringer, Mark G Qian, Marc L Hyer

Mol Cancer Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Matthew O Duffey, Tricia J Vos, Ruth Adams, Jennifer Alley, Justin Anthony, Marc L Hyer

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Mark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, Lee Silverman, Mengkun Zhang, Marc L Hyer

Clin Cancer Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
Jessica J Huck, Mengkun Zhang, Alice McDonald, Doug Bowman, Kara M Hoar, Marc L Hyer

Mol Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections.
Maryla Krajewska, Layton H Smith, Juan Rong, Xianshu Huang, Marc L Hyer

J Histochem Cytochem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer.
Marc L Hyer, Ranxin Shi, Maryla Krajewska, Colin Meyer, Irina V Lebedeva

Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.
Christina L Kress, Marina Konopleva, Vanesa Martínez-García, Maryla Krajewska, Sophie Lefebvre, Marc L Hyer

PLoS One· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FLIP-side of Fas signaling.
Marc L Hyer, Temesgen Samuel, John C Reed

Clin Cancer Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis